CCORF Initiates LifeStance Health(LFST.US) With Buy Rating, Announces Target Price $8
LifeStance Health Gr Analyst Ratings
J.P. Morgan Maintains LifeStance Health(LFST.US) With Hold Rating, Raises Target Price to $8
UBS Adjusts Price Target on Lifestance Health Group to $8.50 From $7.50, Maintains Neutral Rating
Goldman Sachs Maintains LifeStance Health(LFST.US) With Buy Rating, Raises Target Price to $11
Morgan Stanley Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $10
Analysts Conflicted on These Healthcare Names: Ligand Pharma (LGND), GoodRx Holdings (GDRX) and Lifestance Health Group (LFST)
William Blair Initiates LifeStance Health(LFST.US) With Buy Rating
Morgan Stanley Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $10
Morgan Stanley Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $10
Buy Rating for Lifestance Health Group Amid Potential Revenue Boost From Physician Fee Adjustments
LifeStance Health Gr Analyst Ratings
Goldman Sachs Upgrades LifeStance Health(LFST.US) to Buy Rating, Announces Target Price $10
Morgan Stanley Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $10
LifeStance Health Group Is Maintained at Underweight by Barclays
LifeStance Health Gr Analyst Ratings
Barclays Maintains LifeStance Health(LFST.US) With Sell Rating, Maintains Target Price $7
Barclays Sticks to Their Sell Rating for Lifestance Health Group (LFST)
Morgan Stanley Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $10
Morgan Stanley Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $10